The Series D round was led by NEA and values the business at $2.1bn.
"This new investment will help us develop a new generation of AI-powered video experiences that are interactive, real-time, and personalized, offering possibilities we could have only imagined when we founded the company in 2017. I’m excited to bring these experiences to our over 60,000 customers, which range from the world’s largest brands to thousands of small businesses that use Synthesia to communicate internally and externally with unmatched engagement and efficiency,"
Novo Holdings, Glenview Capital and b2venture led the Series E round, which will fund commercial expansion in the US.
"Our commitment to delivering innovative solutions for acute care has never been stronger. This financing round provides the resources to solidify Quanta as the best-in-class solution across the care continuum, to significantly expand our commercial operations, while continuing to introduce enhancements that will strengthen our long-term competitive position."
The financing values the remote work platform at $1.2bn and was led by Silver Lake Waterman.
"Global employment is incredibly complex, involving many moving parts. Oyster emerged as a best-of-breed solution in the category to solve these traditional challenges,"
The financing round featured backing from investors including AstraZeneca, Hitachi Ventures, and Leaps by Bayer.
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
— Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing
The Series D round was backed by strategic investors including AstraZeneca, HAT SGR, Hitachi Ventures, and Leaps by Bayer.
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
— Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing
